Postelimination Cluster of Lymphatic Filariasis, Futuna, 2024

After detection of 2 clinical lymphatic filariasis (LF) cases in a postelimination context in 2023 on the island of Futuna (Wallis and Futuna archipelago), the Wallis and Futuna Health Agency conducted a LF prevalence survey in Futuna in May 2024. This cross-sectional study, carried out among schoo...

Full description

Saved in:
Bibliographic Details
Main Authors: Clément Couteaux, Thibaut Demaneuf, Laurent Bien, Manuel Munoz, Bernadette Worms, Samuel Chésimar, Gwenael Takala, Atonio Lie, Vincent Jessop, Malia Kalemeli Selemago, Valelia Uhila, Monika Toa, Dominique Euller, Cyrille Goarant
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2025-03-01
Series:Emerging Infectious Diseases
Subjects:
Online Access:https://wwwnc.cdc.gov/eid/article/31/3/24-1317_article
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:After detection of 2 clinical lymphatic filariasis (LF) cases in a postelimination context in 2023 on the island of Futuna (Wallis and Futuna archipelago), the Wallis and Futuna Health Agency conducted a LF prevalence survey in Futuna in May 2024. This cross-sectional study, carried out among schoolchildren <18 years of age, identified 5 children with antigenemia, indicating an estimated antigenemia prevalence in Futuna children nearing 2%. The study also confirmed a spatial cluster of cases in the village of Taoa, where the child antigenemia prevalence reached 7.5% (95% CI 2.1%–18.2%), and demonstrated a link between infection and traditional housing. We observed microfilariae in contact cases during secondary investigations. These findings suggest resurgence of LF in a postelimination context, in which the expected child antigenemia prevalence should not exceed 1%. This situation should prompt a new mass drug administration campaign using triple therapy and the reinforcement of epidemiologic and entomologic surveillance.
ISSN:1080-6040
1080-6059